Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nutriband Equity Warrant Exp 30th Sep 2026 NTRBW

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its... see more

Recent & Breaking News (NDAQ:NTRBW)

Nutriband Inc. Reports Revenue Up 113% YoY in Q2

Accesswire September 8, 2022

Nutriband Inc. Provides Update on Seven-for-Six Forward Stock Split

Accesswire August 16, 2022

Nutriband Inc. Details of Seven-for-Six Forward Stock Split

Accesswire August 10, 2022

Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent

Accesswire August 1, 2022

Nutriband Inc. Announces Seven-for-Six Forward Stock Split

Accesswire July 27, 2022

1.2M Shares of Nutriband Inc. to be Cancelled from Total Outstanding Shares Following Final Court Judgment in Favor of the Company

Accesswire July 26, 2022

Nutriband Inc. Registers New Company Branch in Ecuador with Plans to Expand into the South American Market

Accesswire July 22, 2022

Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Accesswire July 21, 2022

Nutriband Inc. Successfully Obtains Court Verdict for Recovery of Shares Constituting 15% of Its Total Outstanding Shares

Accesswire July 15, 2022

Nutriband Supports Update to CDC Opioid Prescribing Guidelines

Accesswire June 3, 2022

Nutriband Inc. Interview to Air on Bloomberg U.S. on The Redchip Money Report(R)

Accesswire May 27, 2022

Nutriband Inc. to Present at the Emerging Growth Conference on May 25

Accesswire May 20, 2022

Nutriband Inc. Receives Orders for $230,000 in Contract Manufacturing for First 3 Weeks of May

Accesswire May 17, 2022

Nutriband Subsidiary Active Intelligence LLC Registers with FDA as a Medical Device Manufacturer for its AI Kinesiology Tape Product

Accesswire May 11, 2022

Nutriband Inc.'s Patent, 'Abuse and Misuse Deterrent Transdermal System' Published by the United States Patent and Trademark Office Following Recent Issuance Notice

Accesswire February 16, 2022

Nutriband Inc. To Participate in The Benzinga All Access Event on February 4

Accesswire February 4, 2022

Nutriband Issued Full US Patent for Its Aversa(TM) Abuse Deterrent Transdermal Platform by United States Patent and Trademark Office

Accesswire January 28, 2022

Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology

Accesswire January 18, 2022

Nutriband Inc. And Kindeva Drug Delivery Sign Feasibility Agreement to Develop AVERSA(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch

Accesswire January 10, 2022

Nutriband Lead Product Aversa(TM) Fentanyl May Reach Peak Annual Sales of $80-200 Million Based on Market Assessment by Leading Healthcare Consulting Firm

Accesswire January 5, 2022